NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients

NCT04708639

UnknownN/A

Sponsor: Aarhus University Hospital

Conditions: Lung Cancer, ALK Gene Mutation, Resistance, Disease, Mutation

Interventions: Alectinib

Countries: Denmark

Circulating tumor DNA can be used to monitor the treatment effect and identify developing resistance mutations during ALK directed TKI treatment.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Patients with ALK translocated metastatic NSCLC, treated with alectinib as 1st line therapy in routine clinical practice
2. Written (personally dated and signed) informed consent

Exclusion Criteria:

Locations (1)

Aarhus, Denmark